DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saw, Phei Er | ko |
dc.contributor.author | Xu, Xiaoding | ko |
dc.contributor.author | Kang, Bo Ram | ko |
dc.contributor.author | Lee, Jungsul | ko |
dc.contributor.author | Lee, Yeo Song | ko |
dc.contributor.author | Kim, Chungyeul | ko |
dc.contributor.author | Kim, Hyungsin | ko |
dc.contributor.author | Kang, Shin-Hyuk | ko |
dc.contributor.author | Na, Yoo Jin | ko |
dc.contributor.author | Moon, Hong Joo | ko |
dc.contributor.author | Kim, Joo Han | ko |
dc.contributor.author | Park, Youn-Kwan | ko |
dc.contributor.author | Yoon, Wonki | ko |
dc.contributor.author | Kim, Jong Hyun | ko |
dc.contributor.author | Kwon, Taek-Hyun | ko |
dc.contributor.author | Choi, Chulhee | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.contributor.author | Chong, Kyuha | ko |
dc.date.accessioned | 2020-12-16T08:30:07Z | - |
dc.date.available | 2020-12-16T08:30:07Z | - |
dc.date.created | 2020-11-23 | - |
dc.date.created | 2020-11-23 | - |
dc.date.created | 2020-11-23 | - |
dc.date.created | 2020-11-23 | - |
dc.date.issued | 2021-01 | - |
dc.identifier.citation | THERANOSTICS, v.11, no.2, pp.941 - 957 | - |
dc.identifier.issn | 1838-7640 | - |
dc.identifier.uri | http://hdl.handle.net/10203/278572 | - |
dc.description.abstract | Extra-domain B of fibronectin (EDB-FN) is an alternatively spliced form of fibronectin with high expression in the extracellular matrix of neovascularized tissues and malignant cancer cells. In this study, we evaluated the practicality of using EDB-FN as a biomarker and therapeutic target for malignant gliomas (MGs), representative intractable diseases involving brain tumors. Methods: The microarray- and sequence-based patient transcriptomic database 'Oncopression' and tissue microarray of MG patient tissue samples were analyzed. EDB-FN data were extracted and evaluated from 23,344 patient samples of 17 types of cancer to assess its effectiveness and selectivity as a molecular target. To strengthen the results of the patient data analysis, the utility of EDB-FN as a molecular marker and target for MG was verified using active EDB-FN-targeting ultrasmall lipidic micellar nanoparticles (similar to 12 nm), which had a high drug-loading capacity and were efficiently internalized by MG cells in vitro and in vivo. Results: Brain tumors had a 1.42-fold cancer-to-normal ratio (p < 0.0001), the second highest among 17 cancers after head and neck cancer. Patient tissue microarray analysis showed that the EDB-FN high-expression group had a 5.5-fold higher risk of progression than the EDB-FN low-expression group (p < 0.03). By labeling docetaxel-containing ultrasmall micelles with a bipodal aptide targeting EDB-FN (termed APT(EDB)-DSPE-DTX), we generated micelles that could specifically bind to MG cells, leading to superior antitumor efficacy of EDB-FN-targeting nanoparticles compared to nontargeting controls. Conclusions: Taken together, these results show that EDB-FN can be an effective drug delivery target and biomarker for MG. | - |
dc.language | English | - |
dc.publisher | IVYSPRING INT PUBL | - |
dc.title | Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma | - |
dc.type | Article | - |
dc.identifier.wosid | 000585989200028 | - |
dc.identifier.scopusid | 2-s2.0-85096306369 | - |
dc.type.rims | ART | - |
dc.citation.volume | 11 | - |
dc.citation.issue | 2 | - |
dc.citation.beginningpage | 941 | - |
dc.citation.endingpage | 957 | - |
dc.citation.publicationname | THERANOSTICS | - |
dc.identifier.doi | 10.7150/thno.44948 | - |
dc.contributor.localauthor | Choi, Chulhee | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.nonIdAuthor | Saw, Phei Er | - |
dc.contributor.nonIdAuthor | Xu, Xiaoding | - |
dc.contributor.nonIdAuthor | Kang, Bo Ram | - |
dc.contributor.nonIdAuthor | Lee, Jungsul | - |
dc.contributor.nonIdAuthor | Lee, Yeo Song | - |
dc.contributor.nonIdAuthor | Kim, Chungyeul | - |
dc.contributor.nonIdAuthor | Kim, Hyungsin | - |
dc.contributor.nonIdAuthor | Kang, Shin-Hyuk | - |
dc.contributor.nonIdAuthor | Na, Yoo Jin | - |
dc.contributor.nonIdAuthor | Moon, Hong Joo | - |
dc.contributor.nonIdAuthor | Kim, Joo Han | - |
dc.contributor.nonIdAuthor | Park, Youn-Kwan | - |
dc.contributor.nonIdAuthor | Yoon, Wonki | - |
dc.contributor.nonIdAuthor | Kim, Jong Hyun | - |
dc.contributor.nonIdAuthor | Kwon, Taek-Hyun | - |
dc.description.isOpenAccess | Y | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | EDB-Fibronectin | - |
dc.subject.keywordAuthor | Glioma | - |
dc.subject.keywordAuthor | Big Data | - |
dc.subject.keywordAuthor | Biomarkers | - |
dc.subject.keywordAuthor | Micelles | - |
dc.subject.keywordPlus | POLYMERIC MICELLES | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | GLIOBLASTOMA | - |
dc.subject.keywordPlus | RADIOIMMUNOTHERAPY | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | I-131-L19SIP | - |
dc.subject.keywordPlus | PHENOTYPE | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.